Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The invention relates to a novel hemi-succinate salt form of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid and a novel crystalline form thereof, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection.

Abstract: The present invention is directed to an improved process for the preparation of Compounds of Formula (I), which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, which is useful in the treatment of HIV infection.

Abstract: Controlling the charge on toner in a development station of an electrographic reproduction apparatus, wherein data relative to latent image charge carrying member voltage and image density control patches are sensed and development potential to achieve an aim density is calculated therefrom. A delta from an optimum development potential range is calculated, and in response to the determined delta, an amount of liquid charge control agent, from a supply of suitable liquid charge control agent, necessary to be added to the developer material in the development station to bring the toner to substantially a charge level that will enable a desired optimum developer potential is calculated. The calculated amount of liquid charge control agent is then injected directly into the development station.

Abstract: A magnetic brush development station for developing latent image charge patterns supported on a moving image support member of an electrostatographic reproduction apparatus. The magnetic brush development station includes a housing located in operative association with an extended run of the image support member. The housing has a portion constituting a sump for developer material, and a portion defining an opening facing the image support member. Further, the magnetic brush development station includes an applicator for applying developer material to a latent image charge pattern on the image support member to develop such latent image charge pattern. The applicator includes a sleeve located in the last mentioned portion of the housing, above the developer material sump, the sleeve having a development surface operatively associated with the image support member through the opening and configured to complementarily conform to the run of the image support member to define an extended uniform development zone.

Abstract: In an electrostatographic reproduction apparatus utilizing a dielectric member web supported by guide rollers for movement along a travel path in relation to electrostatographic process stations, including a web cleaning station, a web cleaning assembly is mounted so that it operates effectively to remove residual marking particles from the web without adversely effecting web tracking as it moves along its desired travel path. In a preferred embodiment of this invention, the cleaning assembly comprises a housing including a chamber adapted to store removed residual marking particles, and a member engaging the web to break the bonds between the residual marking particles and the web for sweeping such particles from the web into the chamber. The housing is mounted relative to one of the guide rollers for movement therewith as such guide roller guides the web along the desired travel path, and with the sweeping member in operative association with the web.

Abstract: An apparatus for cleaning a surface includes a cleaning element, a housing for holding particles removed from the surface, a passive magnet carried by a particle moving member within the housing, and a driven magnet outside the housing for inducing movement in the passive magnet thereby causing the particle moving member to move and to spread particles within the housing.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.